I am trying to get some info from patient experience forums, nothing come up with ogx-011 or Custirsen. For xtandi or zytiga, there were plenty of info from patients participated in the clinical trials before their approval. I had similar experience with vical's cancer vaccine in comparison with other drugs, such as anti-PD1s. Any one has better info?
About 2.5 months earlier. From various company presentations, I got the impression that the earliest time would be end of April. I was quite encouraged as the KM curve for CRPC is relatively linear and every month counts. My conservative assumption was that the median for the control is 25 months and the treatment arm of 29 months (for a blended of 27). Therefore it needs at least additional 3 months from end of 2013 (original projection of blended 24 to 25 months from Oncogenex) to reach the target of 27+ months. Due to the heterogeneous responses to docetaxol combo therapies from patients, statistic significance is quite difficult to reach without relatively large median survival differences (4+ months).
No. I am adding 3 to months to the median of the control arm of other failed trials whose patients did not benefit from Zytiga. The 17 months median survival in the P2 trial (control arm) is just an outlier.
That's the estimate from Oncogenex. The company stated many times during its investor conferences as well earning calls that the estimated impact of the new drugs to be 4 months longer in the median survival.
The event reached much earlier than I expected from my model (the CEO also projected near the end of first or early second quarter). It looks like the event rate was very close to the company's original projection (24 to 25 months median). All large trials started after 2006 without much benefit of zytiga xtandi (combination with docetaxel, such as Aflibercept, Dasatinid, bevacizumad and others) produced median between 21 to 22.5 months (control arm). Zytiga and Xtandi should add 3 to 4 months to the media which approaches 25 to 26 months. From the company's projection, the overall median for SYNERGY patient is most likely between 24 to 26 months. The chance of statistical significance now is exceedingly low
What happened to Zinc and Alzheimer's disease? As long as there's hype, suck investors in. In a few years, change name again and hopefully create more hype .........
I think ECYT has a potent drug discovery platform and should have decent shot at the conditional EY approval soon. However, the relentless selling by the insiders (everyone with options). It seems that those guys excise their options as soon as allowed and sell the shares the next day. The CEO said that ECYT communicates with EU constantly. I guess they knew something we don't.
Men with hormone-sensitive, metastatic prostate cancer who received docetaxel chemotherapy at the start of standard androgen deprivation therapy (ADT) lived longer than patients who received ADT alone.
• The projected 3-year overall survival data were
o 69.0 percent for men randomized to ADT + docetaxel-based chemotherapy
o 52.5 percent for men randomized to receive ADT alone
• The projected 3-year overall survival data for the men with a high extent of metastatic disease as defined above were
o 63.4 percent for men randomized to ADT + docetaxel-based chemotherapy
o 43.9 percent for men randomized to receive ADT alone
• The study’s independent Data and Safety Monitoring Committee recommended that the study results be made public because this planned interim analysis showed prolongation in overall survival.
these data are going to have significant impact on the management of metastatic prostate cancer because they imply that men with a significant extent of metastatic disease will now start to get docetaxel-based chemotherapy much earlier in the course of their disease than previously.
----Courtesy of The "New" Prostate InfoLink.